
    
      Because the trial was not feasible due to the inability to accrue additional clinical study
      sites and enroll an adequate number of subjects, the FDA released the sponsor from the
      postmarketing requirement on 13 November 2017 and the study was stopped prematurely.
      Therefore, the study did not progress to the Phase 2 portion.
    
  